Heather D Turner
CIK 1403571 · Chief Executive Officer · last filed 2026-05-05
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$25.1K
Companies
7
Total Filings
36
Lifetime Open-Market Net
-$2.95M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Terns Pharmaceuticals, Inc. (TERN) Delisted | Director | — | $52.95 | — | $0 | 4 | 2026-05-05 |
| AVLN | Director | — | $34.56 | — | $0 | 1 | 2026-05-01 |
| LBRX | Chief Executive Officer | — | $45.85 | — | $0 | 1 | 2025-09-12 |
| LYEL | Chief General Counsel | — | $14.33 | — | $0 | 1 | 2022-03-18 |
| SANGAMO THERAPEUTICS, INC (SGMO) Delisted | EVP, General Counsel & Sec. | 19,250 | $0.18 | $3.4K | $0 | 2 | 2019-02-27 |
| ATRA | Former EVP, GC & Sec. | 2,920 | $8.61 | $25.1K | -$656.3K | 8 | 2018-02-12 |
| Orexigen Therapeutics, Inc. (OREX) Delisted | SVP, Gen. Counsel & Secretary | 2,264 | — | — | -$2.29M | 19 | 2015-02-05 |
Recent Filings · Page 2 of 4
36 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-02-08 | ATRA | Tax (F) | −4,434 | -$158.7K | EDGAR |
| 2017-02-10 | ATRA | Sell (S) | −12,215 | -$192.1K | EDGAR |
| 2017-02-08 | ATRA | Grant (A) | +49,500 | $0 | EDGAR |
| 2016-09-23 | ATRA | Grant (A) | — | $0 | EDGAR |
| 2016-03-04 | ATRA | Grant (A) | — | $0 | EDGAR |
| 2016-02-11 | ATRA | Grant (A) | +48,857 | $0 | EDGAR |
| 2015-12-21 | ATRA | Grant (A) | — | $0 | EDGAR |
| 2015-02-05 | Orexigen Therapeutics, Inc. (OREX) Delisted | Grant (A) | — | $0 | EDGAR |
| 2014-12-04 | Orexigen Therapeutics, Inc. (OREX) Delisted | Mixed | — | -$98.3K | EDGAR |
| 2014-11-26 | Orexigen Therapeutics, Inc. (OREX) Delisted | Mixed | — | -$130.8K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.